Aranha Ivan, Venkatesh Yeldur P
Department of Biochemistry and Nutrition, CSIR-Central Food Technological Research Institute (CFTRI), Mysuru, Karnataka, India.
Department of Biochemistry and Nutrition, CSIR-Central Food Technological Research Institute (CFTRI), Mysuru, Karnataka, India.
J Ayurveda Integr Med. 2020 Apr-Jun;11(2):140-146. doi: 10.1016/j.jaim.2017.10.006. Epub 2018 Nov 17.
In traditional medicine, guduchi (Tinospora cordifolia) is considered as an adaptogen with immunomodulatory prowess. A 25 kDa protein from guduchi stem has been characterized as an immunomodulatory protein (ImP).
The aim of this study was to evaluate the intrinsic immunogenicity of guduchi ImP and adjuvant activity using ovalbumin (OVA) as antigen in BALB/c mice.
Mice were given guduchi ImP (30 and 60 μg) by intranasal administration to respective groups (n = 6) on days 1, 14 and thereafter weekly till day 42. Immunogenic response was monitored by serum IgG/IgA levels (days 14, 35 and 50). The adjuvant activity was measured by serum anti-OVA IgG/IgA responses to administration of 30 μg OVA with guduchi ImP. The effect of guduchi ImP on the spleen status was examined by splenic weight (day 50).
Guduchi ImP administration displayed a significant increase in anti-guduchi ImP IgG (5-7 fold) and anti-guduchi ImP IgA (3-4 fold) on day 50 vs. control. Guduchi ImP showed a significant increase in anti-OVA IgG (6-7 fold) and anti-OVA IgA (4-5 fold) on day 50 vs. control. The splenic index of guduchi ImP group increased significantly in both the immune and adjuvant response groups; however, the splenic index in the adjuvant response group was markedly higher.
The results indicate that guduchi ImP is a strong immunogen by itself and enhances the immunogenicity of mucosally-administered antigen in BALB/c mice. Based on the results of this animal study, it appears that guduchi ImP shows a potential for future studies in humans.
在传统医学中，古杜奇（匙叶翼梗五味子）被视为一种具有免疫调节能力的适应原。从古杜奇茎中提取的一种25 kDa蛋白已被鉴定为免疫调节蛋白（ImP）。
本研究旨在以卵清蛋白（OVA）为抗原，评估古杜奇ImP在BALB/c小鼠体内的固有免疫原性和佐剂活性。
分别于第1天、第14天给各实验组（n = 6）的小鼠经鼻给予古杜奇ImP（30 μg和60 μg），此后每周给药一次，直至第42天。通过检测血清IgG/IgA水平（第14天、第35天和第50天）监测免疫原性反应。通过检测给予30 μg OVA与古杜奇ImP后血清抗OVA IgG/IgA反应来测定佐剂活性。在第50天通过脾脏重量检查古杜奇ImP对脾脏状态的影响。
与对照组相比，在第50天给予古杜奇ImP后，抗古杜奇ImP IgG（5 - 7倍）和抗古杜奇ImP IgA（3 - 4倍）显著增加。与对照组相比，在第50天古杜奇ImP使抗OVA IgG（6 - 7倍）和抗OVA IgA（4 - 5倍）显著增加。古杜奇ImP组在免疫反应组和佐剂反应组中的脾脏指数均显著增加；然而，佐剂反应组中的脾脏指数明显更高。
结果表明，古杜奇ImP本身是一种强免疫原，可增强BALB/c小鼠黏膜给药抗原的免疫原性。基于该动物研究结果，古杜奇ImP似乎具有在人类中开展未来研究的潜力。
